Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CCR6 | P51684 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 8/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1061152 | 0.78 | ALDH1A1 (0.48) | TLR9ALDH1A1HSP90AA1ATMNPSR1 | |
| SCHEMBL5956001 | 0.76 | MGLL (0.42) | ALDH1A1HSP90AA1ATMPKMMEN1 | |
| SCHEMBL1068302 | 0.74 | GAA (0.48) | ALDH1A1DDB1CRBNMEN1KMT2A | |
| SCHEMBL617412 | 0.73 | RAB9A (0.42) | ALDH1A1PKMDDB1CRBNMEN1 | |
| Ammonia Solution, Strong SCHEMBL9774304 | 0.73 | GAA (0.47) | ALDH1A1DDB1CRBNMEN1KMT2A | |
| SCHEMBL5320949 | 0.72 | HTT (0.42) | ALDH1A1DDB1CRBNPOLBSMN1; SMN2 | |
| SCHEMBL660307 | 0.71 | GAA (0.43) | ALDH1A1PKMDDB1CRBNMEN1 | |
| SCHEMBL28472385 | 0.70 | TLR9 (0.58) | TLR9ALDH1A1HSP90AA1ATMNPSR1 | |
| SCHEMBL11357026 | 0.69 | TDP1 (0.57) | TLR9ALDH1A1HSP90AA1ATMNPSR1 | |
| SCHEMBL28436940 | 0.69 | CRBN (0.56) | ALDH1A1TDP1DDB1CRBNMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6321998-A | — | — | None | — | — | JP | disclosed |
| EP-4722227-A1 | COMPLEX, PHARMACEUTICAL COMPOSITION, VACCINE, AND APPLICATIONS THEREOF | ENU Pharma, Inc. (JP) | 2026-04-08 | — | — | EP | disclosed |
| US-12559522-B2 | Cell penetrating peptide | ASTELLAS PHARMA INC. (JP) | 2026-02-24 | — | — | US | disclosed |
| WO-2024241964-A1 | COMPLEX, PHARMACEUTICAL COMPOSITION, VACCINE, AND APPLICATIONS THEREOF | 遠友ファーマ株式会社 | 2024-11-28 | — | — | WO | disclosed |
| US-20240317804-A1 | CELL PENETRATING PEPTIDE | ASTELLAS PHARMA INC. (JP) | 2024-09-26 | — | — | US | disclosed |
| US-12018095-B2 | Cell penetrating peptide | ASTELLAS PHARMA INC. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-11712466-B2 | Vaccine composition | TOHOKU UNIVERSITY (JP) | 2023-08-01 | — | — | US | disclosed |
| US-20220356207-A1 | CELL PENETRATING PEPTIDE | ASTELLAS PHARMA INC. (JP) | 2022-11-10 | — | — | US | disclosed |
| US-11414456-B2 | Cell penetrating peptide | ASTELLAS PHARMA INC. (JP) | 2022-08-16 | — | — | US | disclosed |
| US-20210163533-A1 | CELL PENETRATING PEPTIDE | ASTELLAS PHARMA INC. (JP) | 2021-06-03 | — | — | US | disclosed |
| EP-2484698-A1 | HYBRIDOMA PRODUCING ANTI-METHYLATED DNA ANTIBODY AND UTILIZATION OF SAME | Sysmex Corporation (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20120184719-A1 | HYBRIDOMA PRODUCING ANTI-METHYLATED DNA ANTIBODY AND UTILIZATION OF SAME | SYSMEX CORPORATION (JP) | 2012-07-19 | — | — | US | disclosed |
| US-20110111427-A1 | BIOMARKER FOR THE ESTIMATION OF ACUTE RENAL DISORDER AND PROGNOSIS OF THE DISORDER, AND USE OF THE BIOMARKER | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2261660-A1 | BIOMARKER FOR THE ESTIMATION OF ACUTE RENAL DISORDER AND PROGNOSIS OF THE DISORDER, AND USE OF THE BIOMARKER | National University Corporation Nagoya University (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-20090203538-A1 | Method of classifying antibody, method of identifying antigen, method of obtaining antibody or antibody set, method of constructing antibody panel and antibody or antibody set and use of the same | INSTITUTE FOR ANTIBODIES CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2078732-A1 | METHOD OF CLASSIFYING ANTIGEN, METHOD OF IDENTIFYING ANTIGEN, METHOD OF OBTAINING ANTIBODY OR ANTIBODY SET, METHOD OF CONSTRUCTING ANTIBODY PANEL AND ANTIBODY OR ANTIBODY SET AND USE OF THE SAME | Institute for Antibodies Co., Ltd. (JP) | 2009-07-15 | — | — | EP | disclosed |
| US-20070081974-A1 | Antibody targeting osteoclast-associated protein | SANKYO COMPANY, LIMITED (JP) | 2007-04-12 | — | — | US | disclosed |
| US-20070031421-A1 | Inhibitors targeting osteoclast-associated protein | SANKYO COMPANY, LIMITED (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1715038-A1 | ANTIBODY TARGETING OSTEOCLAST-ASSOCIATED PROTEIN | Sankyo Company, Limited (JP) | 2006-10-25 | — | — | EP | disclosed |
| JP-H06321998-A | ANTI-FUMONISIN MONOCLONAL ANTIBODY, HYBRIDOMA, HAPTEN ANTIGEN AND THEIR PRODUCTION | KIKKOMAN CORP | 1994-11-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184719-A1 | HYBRIDOMA PRODUCING ANTI-METHYLATED DNA ANTIBODY AND UTILIZATION OF SAME | DNMT1, DNMT3A, MPG | TLR9 205/4885ALDH1A1 3217/4885HSP90AA1 3076/4885 |
| US-12559522-B2 | Cell penetrating peptide | SLC29A1, SLC29A2, DCX | TLR9 1914/4885ALDH1A1 4864/4885HSP90AA1 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.